Revance Therapeutics, Inc.
RVNCDelisted Feb 6, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479290
Revance Therapeutics, Inc. was delisted on Feb 6, 2025; its insiders filed their last Form 4 on Feb 6, 2025; 174 institutions reported holding it in 13F filings for Q4 2024, worth $249.2M in total; Fairfax Financial was the only superinvestor holding it.
Holders of 5% or more of RVNC
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Revance Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Teoxane SA | 13D/A | 6.20%6.55M shares | 0.00 ppfrom 6.20% | Dec 19, 20243 filings | Jan 30, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
24 Schedule 13D and 13G filings on Revance Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 15, 20254:33 PM ET | Glazer Capital, LLCand 1 other | 13G/A | 0.00%0 shares | −6.87 ppfrom 6.87%Below 5% | Mar 31, 2025 | SEC |
| May 15, 202512:33 PM ET | Beryl Capital Management LLCand 3 others | 13G/A | 0.00%0 shares | −6.10 ppfrom 6.10%Below 5% | Mar 31, 2025 | SEC |
| Mar 6, 202510:52 AM ET | JPMorgan Chase & Co | 13G/A | 0.00%0 shares | −5.40 ppfrom 5.40%Below 5% | Feb 28, 2025 | SEC |
| Feb 13, 20254:02 PM ET | Palo Alto Investors LPand 3 others | 13G/A | 1.54%1.61M shares | –Below 5% | Sep 30, 2024 | SEC |
| Feb 11, 202512:16 PM ET | JPMorgan Chase & Co | 13G | 5.40%5.69M shares | – | Dec 31, 2024 | SEC |
| Feb 6, 20256:19 PM ET | Glazer Capital, LLCand 1 other | 13G | 6.87%7.21M shares | New | Jan 30, 2025 | SEC |
| Jan 30, 20259:01 AM ET | Teoxane SA | 13D/A | 6.20%6.55M shares | 0.00 ppfrom 6.20% | Jan 30, 2025 | SEC |
| Jan 10, 20254:52 PM ET | Beryl Capital Management LLCand 3 others | 13G | 6.10%6.36M shares | New | Jan 2, 2025 | SEC |
| Jan 6, 20259:00 AM ET | Teoxane SA | 13D/A | 6.20%6.55M shares | 0.00 ppfrom 6.20% | Jan 6, 2025 | SEC |
| Dec 19, 20249:00 AM ET | Teoxane SA | 13D/A | 6.20%6.55M shares | – | Dec 19, 2024 | SEC |
| Oct 31, 20241:20 PM ET | Franklin Resources Incand 2 others | 13G/A | 4.60%4.78M shares | –Below 5% | Sep 30, 2024 | SEC |
| Feb 14, 2022 | Palo Alto Investors LP | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Capital World Investors | 13GOld format | – | New | – | SEC |
| Feb 10, 2022 | Vanguard Group Inc | 13GOld format | – | New | – | SEC |
| Feb 8, 2022 | GIC Private Ltd | 13G/AOld format | – | – | – | SEC |
| Feb 4, 2022 | Wellington Management Group LLP | 13G/AOld format | – | – | – | SEC |
| Jan 18, 2022 | JPMorgan Chase & Co | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | ArrowMark Colorado Holdings LLC | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | GIC Private Ltd | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2021 | Essex Woodlands Health Ventures VIII, L.L.C. | 13G/AOld format | – | – | – | SEC |
| Feb 5, 20217:51 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 4, 2021 | Wellington Management Group LLP | 13G/AOld format | – | – | – | SEC |
| Feb 2, 2021 | Franklin Resources Inc | 13G/AOld format | – | – | – | SEC |
| Jan 29, 2021 | JPMorgan Chase & Co | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Revance Therapeutics, Inc. shares.
No Form 144 notices for Revance Therapeutics, Inc. are on file.